continuous and categorical variables, respectively. Outcomes of interest included estimated blood loss, warm ischemia time, estimated glomerular filtration rate at 6 months, length of stay, margin status, Fuhrman grade, tumor size, pathological histology, and symptoms index at presentation RESULTS: Among our cohort, 376 (62%) and 228 (38%) patients with were scheduled for RN and PN, respectively. Of the 228 patients originally scheduled for PN, 12% were converted to RN intraoperatively. A smaller proportion of patients scheduled to undergo PN had clear cell/conventional histology (77% vs 88%; p¼0.001) on pathology compared to patients scheduled for RN. Among patients with clear cell or papillary histology, a larger proportion of patients scheduled for PN had lower Fuhrman grade (24% vs 10.3% had FG 1 or 2; p<0.0001) on pathology than patients scheduled for RN. Of our 604 patients, 111 patients died, 33 from kidney disease. The median follow up time for survivors was 2.0 years from surgery. On multivariable analysis, scheduled PN was non-significantly associated with better OS (HR 0.62; 95% C.I. 0.37, 1.03; p ¼ 0.064), better CSS (HR 0.51; 95% C.I. 0.18, 1.49; p ¼ 0.2), and better RFS (HR 0.56; 95% C.I. 0.29, 1.07; p¼0.081). From the estimates of the hazard ratio, we suspect that the bias related to surgeons choosing PN or RN based on low or high risk disease is not appropriately adjusted for in our model CONCLUSIONS: We found no evidence to suggest that PN has poorer outcomes than RN in patients with pT3a tumors. The inherent benefits of PN on renal function preservation make this approach very attractive even in larger and complex tumors METHODS: Multicenter, retrospective analysis of patients with clinically localized RCC (cT1-2). Patients were stratified by presence of T3a PU and by surgical approach. Primary outcome was recurrence. Secondary outcome was overall survival (OS). Multivariable analysis (MVA) was used for recurrence, and Kaplan-Meier analysis (KMA) was utilized for recurrence free survival (RFS) and OS. RESULTS: We analyzed 2443 patients (1093 RN/1350 PN, mean follow up 69.4 months). Rate of T3a PU was 13.3% (cT1a 6.3%, cT1b 15.3%, cT2 31.6%, p<0.001). Compared to pT1-2 tumors, T3aPU had similar positive margin rates (3.0% vs. 4.3%, p¼0.235) but higher rate of recurrence (7.4% vs. 31.0%, p<0.001) and all-cause mortality (16.1% vs. 27.7%, p<0.001). MVA for recurrence demonstrated T3aPU (OR 2.6, p<0.001), tumor size (OR 1.18, p<0.001), high nuclear grade (OR 1.87, p<0.001), and RN (OR 2.23, p<0.001) to be associated factors. Cumulative risk of recurrence for T3aPU plus high nuclear grade was OR 3.92 (p<0.001). KMA for RFS stratifying T3aPU by cT stage and treatment modality revealed 5 year RFS for PN vs. RN in cT1a (91.1% vs. 74.4%, p¼0.063), cT1b (100.0% vs. 70.8%, p¼0.031) and cT2 (44.7% vs. 43.2%, p¼0.557, figure) . KMA for OS stratifying T3a PU for different cT stage and treatment modality revealed 5 year OS for PN vs. RN in cT1a (95.0% vs. 83.4%, p¼0.074), cT1b (100.0% vs. 74.1%, p¼0.088) and cT2 (83.3% vs. 60.6%, p¼0.207; figure) .
INTRODUCTION AND OBJECTIVES: Pathological upstaging (PU) may be noted after surgical management of clinically localized renal cell carcinoma (RCC). We investigated rates and risk factors for PU in the setting of different clinical stages, as well as impact on PU recurrence and survival, and the effect of nephron sparing surgery in setting of PU.
METHODS: Multicenter, retrospective analysis of patients with clinically localized RCC (cT1-2). Patients were stratified by presence of T3a PU and by surgical approach. Primary outcome was recurrence. Secondary outcome was overall survival (OS). Multivariable analysis (MVA) was used for recurrence, and Kaplan-Meier analysis (KMA) was utilized for recurrence free survival (RFS) and OS. RESULTS: We analyzed 2443 patients (1093 RN/1350 PN, mean follow up 69.4 months). Rate of T3a PU was 13.3% (cT1a 6.3%, cT1b 15.3%, cT2 31.6%, p<0.001). Compared to pT1-2 tumors, T3aPU had similar positive margin rates (3.0% vs. 4.3%, p¼0.235) but higher rate of recurrence (7.4% vs. 31 METHODS: We reviewed our database to identify patients who underwent PN between 1990 and 2015 with PSMs on final pathology. Tumors with malignant pathology were isolated and statistically analyzed for demographics and oncologic follow-up. Cancer-specific survival, overall survival and recurrence-free survival were estimated using the Kaplan-Meier method.
RESULTS: A total of 2297 patients underwent PN at our institution. Of these, 50 (2.2%) patients had PSMs on final pathology. There were 30 (1.3%) patients with renal cell carcinoma (RCC) and 20 (0.9%) patients with benign tumors who had PSMs. Patient demographics for those who had PSMs with malignant pathology reported as median for age of 59 years, BMI of 31 kg/m2 and Charlson Comorbidity Index of 2. The primary tumor size was 3.2 cm (range, 2.0-10.0), nephrometry score was 8.0 (range, 5-10), and median number of resected tumors was 1.0 (range, 1-10). There were 17 (57%) patients with bilateral renal masses at presentation, of these 11 (64%) patients have had prior surgical treatment for RCC including 2 of 3 patients with hereditary RCC. Histology was most commonly clear-cell RCC in 20 (67%), stage was primarily pT1a in 21 (70%), and Fuhrman was grade 2 in 17 (57%) of these tumors.There were 7 (23%), and 5 (17%) patients with PSMs that developed recurrence and metastasis; respectively during a median follow-up of 57 months. Recurrence at the surgical bed was found in 3 patients whereas contralateral and bilateral kidney recurrences were found in 2 patients each. Metastases to bone and lung were found 1 and 4 patients; respectively. As projected by the Kaplan-Meier method in the population with RCC, the 5-year cancer-specific survival, overall survival and recurrence-free survival was 95.8%, 92% and 78.2%; respectively.
CONCLUSIONS: There was a low rate of PSMs in our large cohort of patients undergoing PN despite complexity of these renal masses and disease multifocality at presentation. However; efforts should be made intraoperatively to achieve complete surgical excision with negative margins since patients with PSMs have an increased risk for disease recurrence.
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